[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![USCorpFilings Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1859110030752313345.png) SEC Filings Digest [@USCorpFilings](/creator/twitter/USCorpFilings) on x 4337 followers
Created: 2025-07-09 13:30:08 UTC

$KRYS Product Expansion:

On July 9, 2025, Krystal Biotech, Inc. announced the first patient was dosed in their Phase 1/2 trial for KB801, aimed at treating neurotrophic keratitis; a conference call was also scheduled the same day to discuss this program. Additional materials are available on their website.




XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1942939329686585662/c:line.svg)

**Related Topics**
[$krys](/topic/$krys)

[Post Link](https://x.com/USCorpFilings/status/1942939329686585662)